American Society of Hematology

Figure 1.

$Figure 1. Imatinib inhibits T-cell proliferation. Purified CD3+ T cells were labeled with 0.25 μM CFSE, preincubated for one hour in 10 μM imatinib, then stimulated for 4 days. A representative experiment of 5 is shown in panels A-D; gates are set on the dividing cell population. (A) Effect of imatinib on unstimulated T cells, (B) on T cells stimulated through the TCR Vβ chain with 10 μg/mL SEB, (C) on T cells stimulated through the CD2 receptor with 5 μg/mL PHA, and (D) on T cells stimulated through the CD3/TCR complex with 50 ng/mL 12F6. The effect of imatinib at 10 μM on (E) the fraction of dividing T cells and on (F) the average number of cell divisions of stimulated T cells is shown for 5 independent experiments. Horizontal bars indicate means. Fraction of dividing T cells and average number of cell divisions were calculated using proliferation platform of FlowJo.$

Imatinib inhibits T-cell proliferation. Purified CD3⁺ T cells were labeled with 0.25 μM CFSE, preincubated for one hour in 10 μM imatinib, then stimulated for 4 days. A representative experiment of 5 is shown in panels A-D; gates are set on the dividing cell population. (A) Effect of imatinib on unstimulated T cells, (B) on T cells stimulated through the TCR Vβ chain with 10 μg/mL SEB, (C) on T cells stimulated through the CD2 receptor with 5 μg/mL PHA, and (D) on T cells stimulated through the CD3/TCR complex with 50 ng/mL 12F6. The effect of imatinib at 10 μM on (E) the fraction of dividing T cells and on (F) the average number of cell divisions of stimulated T cells is shown for 5 independent experiments. Horizontal bars indicate means. Fraction of dividing T cells and average number of cell divisions were calculated using proliferation platform of FlowJo.

This Feature Is Available To Subscribers Only